iBio CEO Thomas Isett resigns; interim office of CEO created with Lutz and Brenner

iBio, Inc.

CEO Thomas Isett resigned effective Dec 1, 2022; no disagreement with strategy or policies.
Isett will receive severance: 24 months base salary, pro-rata target bonus, plus COBRA coverage for 18 months.
Board created Office of the CEO, with CFO Robert Lutz and CSO Dr. Martin Brenner filling the role.
Leadership team reports to Board Chair William (Chip) Clark while search for new CEO continues.
Isett remains employee until Dec 31, 2022; will assist with CDMO sale through March 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Robert Lutz

Office of the Chief Executive Officer (joint)

IBIO · iBio, Inc.

Effective: 2022-12-02
Filed: December 2, 2022, 6:59 PM ET

the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.

Departed

Thomas F. Isett

Chief Executive Officer

IBIO · iBio, Inc.

Effective: 2022-12-01
Filed: December 2, 2022, 6:59 PM ET

Mr. Isett resigned as CEO of the Company effective December 1, 2022

Appointed (interim)

Martin Brenner

Office of the Chief Executive Officer (joint)

IBIO · iBio, Inc.

Effective: 2022-12-02
Filed: December 2, 2022, 6:59 PM ET

the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Lutz was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..

Action: appointed
Role: Office of the Chief Executive Officer (joint)

Exact text from the filing

the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas F. Isett resigned as Chief Executive Officer at iBio, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Mr. Isett resigned as CEO of the Company effective December 1, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Brenner was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..

Action: appointed
Role: Office of the Chief Executive Officer (joint)

Exact text from the filing

the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.

View on SEC.gov

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001420720-22-000086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.